Andrew A. F. Hack
CIK 1657434 · Chief Financial Officer · last filed 2026-01-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$206.81M
Companies
7
Total Filings
69
Lifetime Open-Market Net
-$258.51M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Mersana Therapeutics, Inc. (MRSN) Delisted | Director | 0 | $29.08 | $0 | $48.36M | 22 | 2026-01-06 |
| NUVL | Director | 1,449,766 | $123.96 | $179.71M | -$156.54M | 8 | 2024-12-13 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 925,714 | $15.50 | $14.35M | -$151.66M | 15 | 2023-08-10 |
| Allena Pharmaceuticals, Inc. (ALNA) Delisted | Director | — | $0.07 | — | $0 | 3 | 2020-11-18 |
| AVIR | Director | 5,365,659 | $5.05 | $27.10M | $6.00M | 2 | 2020-11-03 |
| BCLS Acquisition Corp. (BLSA) Delisted | Chief Financial Officer | 487,500 | $10.04 | $4.89M | $0 | 1 | 2020-10-26 |
| EDIT | Chief Financial Officer | 0 | $2.95 | $0 | -$4.67M | 17 | 2019-02-06 |
Recent Filings · Page 4 of 7
69 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-08-11 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Mixed | −1,000 | -$24.30M | EDGAR |
| 2021-08-04 | NUVL | Mixed | +3,428,014 | $12.49M | EDGAR |
| 2021-07-30 | NUVL | Grant (A) | — | $0 | EDGAR |
| 2021-06-15 | Mersana Therapeutics, Inc. (MRSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-11 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Sell (S) | — | $0 | EDGAR |
| 2021-06-02 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-20 | Mersana Therapeutics, Inc. (MRSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-12 | Mersana Therapeutics, Inc. (MRSN) Delisted | Buy (P) | +250,000 | $4.59M | EDGAR |
| 2020-11-18 | Allena Pharmaceuticals, Inc. (ALNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-11-03 | AVIR | Mixed | +5,615,659 | $6.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.